| Literature DB >> 26914889 |
Crina Popa1,2, Núria S Coll2, Marc Valls1,2, Guido Sessa3.
Abstract
Type III effectors (T3E) are key virulence proteins that are injected by bacterial pathogens inside the cells of their host to subvert cellular processes and contribute to disease. The budding yeast Saccharomyces cerevisiae represents an important heterologous system for the functional characterisation of T3E proteins in a eukaryotic environment. Importantly, yeast contains eukaryotic processes with low redundancy and are devoid of immunity mechanisms that counteract T3Es and mask their function. Expression in yeast of effectors from both plant and animal pathogens that perturb conserved cellular processes often resulted in robust phenotypes that were exploited to elucidate effector functions, biochemical properties, and host targets. The genetic tractability of yeast and its amenability for high-throughput functional studies contributed to the success of this system that, in recent years, has been used to study over 100 effectors. Here, we provide a critical view on this body of work and describe advantages and limitations inherent to the use of yeast in T3E research. "Favourite" targets of T3Es in yeast are cytoskeleton components and small GTPases of the Rho family. We describe how mitogen-activated protein kinase (MAPK) signalling, vesicle trafficking, membrane structures, and programmed cell death are also often altered by T3Es in yeast and how this reflects their function in the natural host. We describe how effector structure-function studies and analysis of candidate targeted processes or pathways can be carried out in yeast. We critically analyse technologies that have been used in yeast to assign biochemical functions to T3Es, including transcriptomics and proteomics, as well as suppressor, gain-of-function, or synthetic lethality screens. We also describe how yeast can be used to select for molecules that block T3E function in search of new antibacterial drugs with medical applications. Finally, we provide our opinion on the limitations of S. cerevisiae as a model system and its most promising future applications.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26914889 PMCID: PMC4767418 DOI: 10.1371/journal.ppat.1005360
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Fig 1Most common phenotypes observed in S. cerevisiae upon T3E expression.
Black bars indicate total number of effectors described for each phenotype; gray bars, the number also causing growth inhibition.
List of bacterial T3Es studied in budding yeast.
Ref. stands for references. Genera are abbreviated as follows: S. = Salmonella or Shigella, X. = Xanthomonas, E. = Erwinia or Escherichia, P. = Pseudomonas or Pantoea, V. = Vibrio, C. = Chlamydia or Citrobacter.
| Effector | Organism | Approaches used in characterisation | Phenotypes in yeast | Ref. |
|---|---|---|---|---|
|
|
| GTPase assays, mutational analysis | Growth inhibition, GAP activity | [ |
|
|
| Subcellular localization, flow cytometry, actin staining | Growth inhibition, disruption of actin cytoskeleton | [ |
|
|
| Subcellular localization | Vesicle trafficking-dependent nucleus accumulation | [ |
|
|
| Functional mutational analysis | Identification of critical residues for nuclear targeting | [ |
|
|
| Viability assays, actin staining, indirect immunofluorescence | Growth inhibition/cytotoxicity, disruption of actin cytoskeleton | [ |
|
|
| Phenotype suppression screen, acetylation assays, yeast two-hybrid interactions | Growth arrest, inability to respond to the α factor | [ |
|
|
| Mutational analysis, phenotypic analysis of homologues | Growth inhibition | [ |
|
|
| CPY-Inv reporter system, Tet-off expression system | Growth inhibition, perturbation of vesicle trafficking | [ |
|
|
| MAPK phosphorylation assays | Growth inhibition, activation of MAPK signalling | [ |
|
|
| Fluorescence staining, functional domain analysis, enzymatic assays | Growth inhibition, actin depolarization | [ |
|
|
| Subcellular localization, mutational analysis, indirect immunofluorescence, enzymatic assays, MAPK phosphorylation assays, protein affinity purification | Growth inhibition/growth arrest, disruption of cytoskeleton, inhibition of MAPK signalling, interaction with yeast Cdc42 G12V and Cdc24 | [ |
|
|
| Screen for effector-triggered phenotypes, fluorescence staining, MAPK phosphorylation assays | Growth inhibition, disruption of actin cytoskeleton | [ |
|
|
| Fluorescence staining, functional mutational analysis, co-immunoprecipitation, MAPK phosphorylation assays | Growth inhibition, interaction with hCdc42 in yeast | [ |
|
|
| Phenotype suppression screen, lacZ reporter assays, co-immunoprecipitation assays, fluorescent staining | Growth inhibition, inhibition of MAPK signalling, interaction with GEF Cdc24 | [ |
|
|
| Cell cycle functional assays | No effect on cell viability or alteration of cell cycle | [ |
|
|
| Fluorescence staining, functional mutational analysis | Growth inhibition /Cytotoxicity | [ |
|
|
| Fluorescence staining, thin-layer chromatography of lipids, enzymatic assays | Growth inhibition/cytotoxicity, membrane alteration, lipase activity | [ |
|
|
| Functional domain analysis | Growth inhibition | [ |
|
|
| Mutational analysis, fluorescence staining, flow cytometry | Growth inhibition, disruption of actin cytoskeleton, inhibition of DNA synthesis | [ |
|
|
| Phenotype suppression screen, screen for inhibitors of effector toxicity, functional mutational analysis, enzymatic assays | Growth inhibition, modulation of Rho G signalling, identification of exosin, a ExoS inhibitor drug | [ |
|
|
| MAPK phosphorylation assays | Growth inhibition/growth arrest, inhibition of MAPK signalling | [ |
|
|
| Screen for effector-triggered phenotypes | Growth inhibition, MAPK interference | [ |
|
|
| Actin staining, indirect immunofluorescence | Disruption of microtubule structure | [ |
|
|
| Fluorescence staining, immunofluorescence, activation of MAPK signalling | Growth inhibition, cell cycle alteration | [ |
| EspB, D, F, G, Map and Tir |
| Protein affinity-purification, μLC-MS/MS | Interaction of EspB, D, F, G, Map and Tir with host proteins | [ |
|
|
| Screen for effector-triggered phenotypes | Growth inhibition | [ |
|
|
| Screen for inhibitors of effector toxicity, FACS, fluorescence staining, phenotypic analysis of homologues | Growth inhibition/growth arrest, disruption of microtubule structure, identification of two inhibitor drugs | [ |
|
|
| Phenotype suppression screen, mRNA profiling, yeast two hybrid | Growth inhibition, modulation of Rho G signalling | [ |
|
|
| Phenotype suppression screen, MAPK phosphorylation assays, mRNA profiling | Inhibition of MAPK signalling | [ |
|
|
| Functional domain analysis, enzymatic assays | E3 ubiquitin ligase for MAPKKK | [ |
|
|
| Screen for effector-triggered phenotypes | Growth inhibition | [ |
|
|
| Phenotype suppression screen | Growth inhibition, identification of IpaJ substrates | [ |
|
|
| Cell death assays | Suppression of stress-induced cell death | [ |
|
|
| Viability assays | Suppression of Bax-induced PCD | [ |
|
|
| Screen for effector-triggered phenotypes, cell viability assays, indirect immunofluorescence, domain analysis | Growth inhibition/cell death, loss of respiration | [ |
|
|
| Functional domain analysis | Growth inhibition /cell death | [ |
|
|
| Screen for effector-triggered phenotypes, functional mutational analysis, | Growth inhibition under stress, inhibition of MAPK signalling | [ |
|
|
| Functional mutational analysis | Growth inhibition | [ |
|
|
| Screen for effector-triggered phenotypes, functional mutational analysis | Growth inhibition/growth arrest & cell death, growth inhibition under stress | [ |
|
|
| Synthetic lethality screen, | Perturbation of vesicle trafficking | [ |
|
|
| Fluorescent staining, cell viability assays | Growth inhibition, disruption of actin cytoskeleton, perturbation of trafficking | [ |
|
|
| Phenotype suppression screen, actin staining, HPLC, cell labelling and thin-layer chromatography, phosphorylation assays | Disruption of cytoskeleton, down-regulation of sphingolipid pathway | [ |
Fig 2Yeast cellular processes targeted by bacterial T3Es.
The key processes targeted are marked in yellow and their components separated by dotted areas. Plant-associated effectors (green squares) and animal-associated effectors (red squares) are indicated next to the activities they modulate. Arrows indicate activation and T symbols indicate inhibition. Abbreviations: UPR: unfolded protein response; SPT: serine palmitoyltransferase; LCB: long chain bases; GSH: glutathione; Trxs: thioredoxins; P: phosphate group. Other common abbreviations are given in the text.